logo
Twitter
Discord
Email
logo
Terns Pharmaceuticals, Inc.

Terns Pharmaceuticals, Inc.

NASDAQ•TERN
CEO: Ms. Amy L. Burroughs M.B.A.
Sector: Healthcare
Industry: Biotechnology
Listing Date: 2021-02-05
Terns Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops small-molecule product candidates for the treatment of oncology, metabolic dysfunction-associated steatohepatitis (MASH), and obesity. The company develops TERN-701, an allosteric BCR-ABL tyrosine kinase inhibitor (TKI) that is in phase 1 clinical trial for chronic myeloid leukemia (CML), a form of cancer that starts in bone marrow. It also develops TERN-501, a thyroid hormone receptor beta agonist with enhanced liver distribution and metabolic stability that is in Phase IIa clinical trial for the treatment of MASH; and TERN-601, a small-molecule Glucagon-Like Peptide-1 receptor agonist program that is intended to orally be administered for obesity. The company was incorporated in 2016 and is headquartered in Foster City, California.
Contact Information
1065 East Hillsdale Boulevard, Suite 100, Foster City, CA, 94404, United States
650-525-5535
www.ternspharma.com
Market Cap
$4.05B
P/E (TTM)
-44.9
42.1
Dividend Yield
--
52W High
$48.26
52W Low
$1.87
52W Range
93%
Rank55Top 68.5%
3.0
F-Score
Modified Piotroski Analysis
Based on 7-year fundamentals
Weak • 3 / 9 points
Scoring Range (0-9)
8-9: Excellent Value
6-7: Strong Fundamentals
4-5: Average Quality
0-3: Weak Performance
Data Period: 2018-2024

Financial Dashboard

Q3 2025 Data

Revenue

$0.00+0.00%
4-Quarter Trend

EPS

-$0.27-3.57%
4-Quarter Trend

FCF

-$19.77M+20.16%
4-Quarter Trend

2025 Q3 Earnings Highlights

Key Highlights

TERN-701 Clinical Data Update Nine-month data shows 75% cumulative MMR rate by 24 weeks in CARDINAL trial efficacy-evaluable patients.
Cash Runway Secured Cash reserves of $150.7M are sufficient to fund planned operating expenses and capital requirements into 2028.
R&D Investment Rises Nine-month R&D expenses increased $6.9M to $59.0M, driven by clinical and preclinical program advancement.
Stock-Based Costs Decline Total stock-based compensation expense was $10.0M for nine months, decreasing from $12.6M prior period.

Risk Factors

Regulatory Agency Disruption FDA funding cuts and potential government shutdowns could hinder timely guidance and product approval timelines.
Metabolic Asset Pivot Company decided not to advance TERN-601 or invest further in TERN-501 or the TERN-800 series assets.
Substantial Future Funding Expect continued net operating losses requiring substantial additional funding to support ongoing research and development activities.
Trade Policy Uncertainty Evolving global trade policies and tariffs, especially concerning China operations, pose risks to supply chain costs.

Outlook

Focus on TERN-701 Advancement Strategy reiterates rapid advancement of TERN-701 program across all Chronic Myeloid Leukemia treatment lines.
Seeking TERN-501 Partner Actively seeking strategic partner to advance TERN-501 program for obesity and other metabolic disorders.
Increased Operating Expenses Expect expenses to increase as development continues for ongoing clinical trials and future regulatory submissions.

Peer Comparison

Revenue (TTM)

Arvinas, Inc.ARVN
$312.30M
+93.9%
Day One Biopharmaceuticals, Inc.DAWN
$133.67M
+30.4%
Nurix Therapeutics, Inc.NRIX
$83.69M
+48.3%

Gross Margin (Latest Quarter)

Day One Biopharmaceuticals, Inc.DAWN
88.7%
-9.6pp
UroGen Pharma Ltd.URGN
85.3%
-4.5pp
Nurix Therapeutics, Inc.NRIX
36.7%
+377.4pp

Key Metrics

Symbol
Market Cap
P/E (TTM)
ROE (TTM)
Debt to Assets
TERN$4.05B-44.9-27.4%0.4%
OLMA$2.27B-18.9-41.5%0.4%
NRIX$1.47B-6.6-53.6%10.8%

Long-Term Trends

Last 4 Quarters
Revenue
Net Income
Operating Cash Flow
4Q Revenue CAGR
N/M
Revenue Volatile
4Q Net Income CAGR
N/M
Profitability Shift
Cash Flow Stability
0%
Cash Flow Needs Attention

Research & Insights

Next earnings:Mar 19, 2026
|
EPS:-$0.30
|
Revenue:-
Reports
All Years

  • Form 10-Q - Q3 2025

    Period End: Sep 30, 2025|Filed: Nov 10, 2025|
    Revenue: $0.00+0.0%
    |
    EPS: $-0.27-3.6%
    N/A

  • Form 10-Q - Q2 2025

    Period End: Jun 30, 2025|Filed: Aug 5, 2025|
    Revenue: $0.00+0.0%
    |
    EPS: $-0.26-16.1%
    N/A

  • Form 10-Q - Q1 2025

    Period End: Mar 31, 2025|Filed: May 8, 2025|
    Revenue: $0.00+0.0%
    |
    EPS: $-0.26-13.3%
    N/A

  • Form 10-K - FY 2024

    Period End: Dec 31, 2024|Filed: Mar 20, 2025|
    Revenue: $0.00+0.0%
    |
    EPS: $-1.12+11.8%
    N/A

  • Form 10-Q - Q3 2024

    Period End: Sep 30, 2024|Filed: Nov 12, 2024|
    Revenue: $0.00+0.0%
    |
    EPS: $-0.28-33.3%
    N/A

  • Form 10-Q - Q2 2024

    Period End: Jun 30, 2024|Filed: Aug 5, 2024|
    Revenue: $0.00+0.0%
    |
    EPS: $-0.31+24.0%
    N/A

  • Form 10-Q - Q1 2024

    Period End: Mar 31, 2024|Filed: May 13, 2024|
    Revenue: $0.00+0.0%
    |
    EPS: $-0.30-3.2%
    N/A

  • Form 10-K - FY 2023

    Period End: Dec 31, 2023|Filed: Mar 14, 2024|
    Revenue: $0.00+0.0%
    |
    EPS: $-1.27+24.0%
    N/A